Merck Shares Reach New Highs Driven by Strong Cancer Drug Sales
Rahway, Wednesday, 19 August 2026.
Merck stock hit a 52-week high in August 2026, supported by robust oncology revenue and a 70% annual gain, demonstrating strong investor confidence in its long-term product pipeline.
A Surge to New Heights Amid Strong Financials
On August 17, 2026, Merck & Co., Inc. (NYSE: MRK) shares closed at $135.84 on the New York Stock Exchange, trading just below its 12-month high of $135.97 [3]. This performance capped a remarkable 12-month price appreciation of 69.7% [3], representing a market capitalization of $335.8 billion [3]. During the same session, the stock even reached a fresh 52-week high of $137.17 [2]. This upward momentum follows an analyst upgrade on August 17, 2026, which raised Merck’s rating from Neutral to Outperform and increased the price target from $120 to $143 [3]. Additionally, the stock offers a forward dividend yield of 2.5% based on an annualized dividend payout of $3.40 per share [3].
Keytruda and Portfolio Growth Drive Revenue
The rally is heavily supported by the company’s Q2 2026 financial results. Merck reported Q2 2026 revenue of $16.61 billion, which represents a 5% year-over-year increase [2][3]. This growth was primarily driven by its powerhouse oncology portfolio, specifically Keytruda, which saw sales increase by 4% to $8.4 billion [2]. The pharmaceutical giant’s business structure remains highly concentrated, with its pharmaceutical segment accounting for approximately 89% of revenue (growing at about 5% year-over-year as of Q2 2026) and its Animal Health division contributing roughly 10% of revenue (growing at about 8% year-over-year) [1].
Navigating Pipeline Acquisitions and the Paper Loss
Despite the strong top-line performance, the headline figures for Q2 2026 showed a net loss of $0.13 per share [1]. However, this loss was driven by significant one-time in-process research and development (IPR&D) charges totaling $5.93 per share, stemming from the acquisitions of Cidara Therapeutics ($3.62 per share) and Terns Pharmaceuticals ($2.31 per share) [1]. When normalizing these charges, Merck’s estimated 2026 earnings power stands at $8.60 to $8.70 per share, compared to $8.98 per share in 2025 [1]. This explains why the trailing twelve months P/E ratio, which reached approximately 108x, is considered by analysts to be mechanically distorted by these one-time pipeline investments [1].
New Launches Offset Financial Leverage
To sustain its valuation, Merck is heavily relying on its new-launch products. These products—including Winrevair, Keytruda Qlex, Capvaxive, Ohtuvayre, Enflonsia, Idvynso, Bravecto Quantum, and Numelvi—generated $1.5 billion in Q2 2026 revenue, a significant jump from the $0.6 billion recorded in Q2 2025 [1]. Winrevair has been a particular standout, growing by 75% to reach $588 million, while Keytruda Qlex recorded $463 million [1]. However, these aggressive acquisitions have also impacted the company’s balance sheet, pushing its total-debt-to-total-capital ratio from 36% in FY 2025 to over 41% in the first half of 2026 [1].
Addressing the Looming Patent Cliff and Valuation Premiums
While the present looks bright, long-term investors are closely monitoring the “patent cliff” associated with Keytruda. The blockbuster drug is scheduled to lose its U.S. patent protection in December 2028, with market analysts projecting a 40% to 60% volume erosion within 12 months of biosimilar entry [1]. Furthermore, the Inflation Reduction Act (IRA) is poised to bring government pricing pressure on Keytruda starting in January 2028 [1]. The IRA’s impact has already been felt within Merck’s portfolio, having reduced Januvia prices by 79% [1]. This patent cliff is a known risk that has already been integrated into market pricing [1].
Regulatory Headwinds and Forward Guidance
In addition to pipeline expansion, Merck’s regulatory progress has provided a tailwind. On May 22, 2026, a European medicines committee issued a positive opinion recommending the combination of Keytruda and Padcev for certain bladder cancer patients, with a final European Commission review expected by Q3 2026 [4]. This regulatory milestone helped drive a 59% increase in MRK stock value in the 12 months preceding August 18, 2026, during which retail sentiment remained neutral [4]. Currently, Merck’s stock trades at a 13.3% premium relative to its “GF Value” estimate of $119.85 [3]. The premium is calculated as 13.342% [3]. Looking ahead, Merck has reaffirmed its full-year 2026 revenue guidance in the range of $65.8 billion to $67 billion [2][3].